abacavir + lamivudine + zidovudine

**Abacavir + lamivudine + zidovudine** is an oral fixed-dose antiretroviral combination marketed as **Trizivir**. It contains three synthetic nucleoside analogue reverse transcriptase inhibitors: abacavir, lamivudine, and zidovudine. After intracellular phosphorylation to active nucleotide analogues, the components competitively inhibit HIV-1 reverse transcriptase and terminate viral DNA-chain elongation, suppressing HIV replication. The combination is indicated for treatment of HIV-1 infection, either alone in appropriate patients or with other antiretroviral agents. The fixed-dose tablet contains abacavir 300 mg, lamivudine 150 mg, and zidovudine 300 mg. Important risks include potentially fatal abacavir hypersensitivity, particularly in people positive for HLA-B*5701; zidovudine-associated anemia, neutropenia, and myopathy; lactic acidosis/hepatomegaly with steatosis; and hepatitis B exacerbation after stopping lamivudine-containing treatment. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3354e50f-4dc5-413f-b5ae-87353ab8913d))

Brand names

Trizivir

Other names

ABC + 3TC + ZDVABC/3TC/ZDVabacavir + lamivudine + zidovudineabacavir/lamivudine/zidovudineTZVZDV + 3TC + ABCzidovudine + lamivudine + abacavirzidovudine/lamivudine/abacavir